Bifidobacterium longum subsp. infantis BB-02 attenuates acute murine experimental model of inflammatory bowel disease

Beneficial microbes - Tập 6 Số 3 - Trang 277-286 - 2015
Samir de Deus Elian Andrade1, E.L.S. Souza1, Angélica T. Vieira2,3,4, Mauro M. Teixeira5, Rosa Maria Esteves Arantes6, Jacques R. Nicoli1, Flaviano S. Martins1
1Department of Microbiology, Institute of Biological Sciences, Federal University of Minas Gerais, Avenida Presidente Antônio Carlos 6627, Pampulha Campus UFMG, 31270-901 Belo Horizonte, MG, Brazil
2Belo Horizonte, MG, Brazil
3Department of Biochemistry and Immunology, Institute of Biological Sciences, Federal University of Minas Gerais, Avenida Presidente Antônio Carlos 6627, Pampulha Campus UFMG, 31270-
4Department of Microbiology, Institute of Biological Sciences, Federal University of Minas Gerais, Avenida Presidente Antônio Carlos 6627, Pampulha Campus UFMG, 31270-
5Department of Biochemistry and Immunology, Institute of Biological Sciences, Federal University of Minas Gerais, Avenida Presidente Antônio Carlos 6627, Pampulha Campus UFMG, 31270-901 Belo Horizonte, MG, Brazil
6Department of General Pathology, Institute of Biological Sciences, Federal University of Minas Gerais, Avenida Presidente Antônio Carlos 6627, Pampulha Campus UFMG, 31270-901 Belo Horizonte, MG, Brazil

Tóm tắt

Inflammatory bowel diseases (IBD) are chronic inflammatory conditions, characterised by remissions and relapses episodes, whose main manifestations are ulcerative colitis and Crohn's disease. Ulcerative colitis (UC), one of the main forms of IBD, has as standard treatment the use of corticosteroids and anti-inflammatory drugs. The use of antibiotics has been also reported, but the possible adverse effects, such as disturbance of the indigenous microbiota or resistance induction, should be taken into consideration, and thus the use of probiotics emerges as a possible alternative option of treatment. In this study, the oral administration of Bifidobacterium longum subsp. infantis BB-02 was evaluated as a preventive strategy for acute experimental UC induced in female BALB/c mice by ingestion of 3.5% dextran sulphate sodium in drinking water during 7 days. During this time, the daily disease activity index was evaluated, and on the seventh day the animals were euthanised to collect intestines and liver for analysis. Treatment with the probiotic resulted in clinical improvement of the animals. The histological and morphometric analyses showed a reduction of lesions and oedema in the gut, but there was no increase in the production of mucin. The dosage of secretory immunoglobulin A was significantly higher in the colitis group and reduced in the group treated with the probiotic. There was also a reduction in the inflammation of the colon, as demonstrated by a decrease in neutrophils infiltration, and KC/CXCL-1 levels. The intestinal permeability, which is typically increased during the onset of IBD, was also reduced by treatment with probiotic. Based on these data, it can be concluded that the bacterium B. infantis BB-02 has a probiotic potential for the attenuation of UC, but further studies should be conducted to verify the mechanism of protective action of the bacterium.

Từ khóa


Tài liệu tham khảo

10.1371/journal.pone.0013676

10.2169/internalmedicine.37.253

10.1128/AEM.02493-10

10.1111/j.1572-0241.2005.41794.x

10.1016/j.jpeds.2005.03.054

10.1189/jlb.0207118

10.1111/j.1572-0241.1999.01223.x

10.1080/003655201750153377

Laboratory Investigation, 6, 238

10.1097/01.mcg.0000159217.47419.5b

10.1056/NEJMra1102942

10.1080/00365520801943354

10.1016/j.bcp.2011.09.004

10.1016/S0016-5085(03)00171-9

10.1053/gast.2000.9370

10.3748/wjg.v17.i34.3916

Journal of Clinical Gastroenterology, 44, 385, 10.1097/MCG.0b013e3181cb4233

10.1097/00042737-200306000-00017

10.1023/A:1005588911207

10.1017/S0022029912000684

10.1002/path.904

10.1097/01.MIB.0000158158.55955.de

10.1111/j.1572-0241.1999.00940.x

10.1023/A:1010659803912

10.1038/nri1373

10.1007/s00203-009-0491-x

10.1016/j.micinf.2012.12.007

10.1038/nrmicro2538

10.1111/j.1440-1746.1997.tb00375.x

10.1159/000354891

10.1023/B:DDAS.0000017459.59088.43

Journal of Biomedicine and Biotechnology, 2012, 718617

Zeitschrift für Gastroenterologie, 31, 129

10.1023/A:1018843104511

10.1016/S0140-6736(98)06343-0

10.1111/j.1572-0241.2001.03743.x

10.1034/j.1600-065X.2000.17706.x

10.1016/0022-1759(85)90242-X

10.1016/S0002-9440(10)65128-0

10.1371/journal.pone.0001308

10.2353/ajpath.2009.090093

10.1038/sj.bjp.0706321

Frontiers in Immunology, 4, 445

10.1038/nprot.2007.41

10.1038/nature06005

10.1371/journal.pone.0006073

10.1111/j.1572-0241.2002.05431.x

10.1111/j.1462-5822.2006.00836.x

Thông tin
Thông tin xuất bản

Beneficial microbes

Tập 6 Số 3

277-286

Thông tin tác giả